Company intelligence / Profile preview

Radium Capital

Perth, Western Australia, Australia

Ownership: Private
Development stage: Other

Overview

Radium Capital is Australia's market leader in R&D finance, offering non-dilutive capital by pre-financing R&D tax incentive refunds for innovative businesses across various sectors, including biotech and medtech. Their 'Radium Advance' product provides rapid access to up to 80% of expected refunds, facilitating cash flow and reinvestment in R&D. They have deployed over $900 million in funding.

Industry: Investors

Partnerships

Cicada Innovations (deep tech incubator partnership)Stuart Therapeutics (client/finance relationship for Phase 3 R&D)

Beyond the preview

Go deeper on Radium Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Radium Capital.

Explore the full profile